UBS Group
XLO icon

UBS Group’s Xilio Therapeutics XLO Stock Holding History

UBS Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134 Sell
14
-4,024
-100% -$33.6K ﹤0.01% 10066
2026
Q1 		$34K Buy
4,038
+4,023
+26,820% +$32.9K ﹤0.01% 7613
2025
Q4 		$130 Sell
15
-960
-98% -$10.1K ﹤0.01% 10158
2025
Q3 		$11.5K Sell
975
-16,166
-94% -$162K ﹤0.01% 8483
2025
Q2 		$163K Buy
17,141
+5,491
+47% +$58K ﹤0.01% 6862
2025
Q1 		$118K Sell
11,650
-6,164
-35% -$77.5K ﹤0.01% 6915
2024
Q4 		$238K Buy
17,814
+16,690
+1,485% +$230K ﹤0.01% 6346
2024
Q3 		$12.4K Buy
1,124
+1,110
+7,929% +$13.6K ﹤0.01% 7637
2024
Q2 		$191 Hold
14
– – ﹤0.01% 9085
2024
Q1 		$217 Hold
14
– – ﹤0.01% 8726
2023
Q4 		$111 Hold
14
– – ﹤0.01% 8913
2023
Q3 		$424 Hold
14
– – ﹤0.01% 8504
2023
Q2 		$527 Hold
14
– – ﹤0.01% 8189
2023
Q1 		$637 Hold
14
– – ﹤0.01% 8947
2022
Q4 		$541 Hold
14
– – ﹤0.01% 10139
2022
Q3 		$1K Sell
14
-187
-93% -$7.26K ﹤0.01% 10055
2022
Q2 		$9K Buy
201
+132
+191% +$6.98K ﹤0.01% 8180
2022
Q1 		$7K Sell
69
-215
-76% -$34K ﹤0.01% 8851
2021
Q4 		$64K Buy
+284
New +$67.7K ﹤0.01% 6704

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's XLO Position: Q2 2026 in Review

UBS Group reduced its Xilio Therapeutics (XLO) stake by 100% in Q2 2026, selling an estimated $33.6K and leaving 14 shares worth $134. The position accounts for ﹤0.01% of the portfolio, ranked #10066.

UBS Group first reported a position in XLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $238K in Q4 2024. 24 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • UBS Group held 14 shares of Xilio Therapeutics worth $134 as of Q2 2026.
  • UBS Group sold 4,024 Xilio Therapeutics shares in Q2 2026, an estimated $33.6K.
  • Xilio Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10066 holding.
  • UBS Group first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • UBS Group's Xilio Therapeutics position peaked at $238K in Q4 2024.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.